Premium
Comparison between piperacillin/tazobactam and cefepime monotherapies as an empirical therapy for febrile neutropenia in children with hematological and malignant disorders: A prospective, randomized study
Author(s) -
Sano Hirozumi,
Kobayashi Ryoji,
Suzuki Daisuke,
Kishimoto Kenji,
Yasuda Kazue,
Kobayashi Kunihiko
Publication year - 2015
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25178
Subject(s) - medicine , cefepime , piperacillin/tazobactam , febrile neutropenia , piperacillin , tazobactam , neutropenia , blood cancer , adverse effect , empirical treatment , pediatrics , intensive care medicine , chemotherapy , cancer , antibiotics , microbiology and biotechnology , genetics , antibiotic resistance , imipenem , bacteria , pseudomonas aeruginosa , biology
To evaluate the efficacy and safety of piperacillin/tazobactam (PIPC/TAZ) or cefepime (CFPM) monotherapy for febrile neutropenia (FN) in children, a total of 53 patients with 213 febrile episodes were randomly treated with either PIPC/TAZ 337.5 mg/kg/day, or CFPM 100 mg/kg/day. No significant differences were observed in the success rates of the PIPC/TAZ and CFPM treatments (62.1% vs. 59.1%, P = 0.650). Furthermore, no differences were noted in the rates of new infection and mortality, and no serious adverse effects occurred in either of groups. Both PIPC/TAZ and CFPM were effective and safe as an empirical therapy for FN in children. Pediatr Blood Cancer 2015;62:356–358. © 2014 Wiley Periodicals, Inc.